RGN-259: Preliminary Phase II data

Preliminary data from a double-blind Phase II trial in 9 patients showed that RGN-259 given 6 times daily for 28 days significantly improved signs and symptoms of severe dry eye, including ocular discomfort and corneal fluorescein staining, at various time points throughout the trial and at 28 days post-treatment vs. vehicle-treated controls. Specifically, RGN-259 significantly reduced ocular discomfort by 35.1% and total corneal fluorescein staining by 59.1% from baseline at 28 days post-treatment vs. vehicle controls (p=0.0141 and p=0.0108, respectively). RGN-259 was well tolerated...